A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia

Trial Profile

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2015

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE; ASPIRE OPEN-LABEL
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 07 May 2013 Planned End Date changed from 1 Sep 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 14 Jun 2012 Planned number of patients changed from 800 to 1224 as reported by ClinicalTrials.gov record (parent trial: NCT00731549).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top